These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28814907)

  • 1. New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer.
    Niki M; Yokoi T; Kurata T; Nomura S
    Lung Cancer (Auckl); 2017; 8():91-99. PubMed ID: 28814907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-Derived Microparticles are an Important Biomarker in Patients with Cancer-Associated Thrombosis.
    Yamanaka Y; Sawai Y; Nomura S
    Int J Gen Med; 2019; 12():491-497. PubMed ID: 32099444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
    Shibata Y; Kobayashi N; Sato T; Nakashima K; Kaneko T
    Thorac Cancer; 2020 May; 11(5):1258-1264. PubMed ID: 32163231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma.
    Nomura S; Ito T; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Satake A; Ishii K
    J Blood Med; 2018; 9():1-7. PubMed ID: 29403323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
    Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic and predictive significance of plasma type 1 plasminogen activator inhibitor and endoglin in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.
    Bal O; Ekinci AS; Dogan M; Atay C; Demirci A; Oksuzoglu B; Kilic S
    J Cancer Res Ther; 2019; 15(1):48-53. PubMed ID: 30880754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
    Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
    Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
    Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.
    Su CY; Liu YP; Yang CJ; Lin YF; Chiou J; Chi LH; Lee JJ; Wu AT; Lu PJ; Huang MS; Hsiao M
    PLoS One; 2015; 10(7):e0133411. PubMed ID: 26230665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.
    Naumnik W; Nilklińska W; Ossolińska M; Chyczewska E
    Folia Histochem Cytobiol; 2009; 47(4):703-9. PubMed ID: 20430742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients.
    Handke NA; Rupp ABA; Trimpop N; von Pawel J; Holdenrieder S
    Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33672622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response.
    Setiawan L; Setiabudy R; Kresno SB; Sutandyo N; Syahruddin E; Jovianti F; Nadliroh S; Mubarika S; Setiabudy R; Siregar NC
    Cancer Biomark; 2024; 39(2):137-153. PubMed ID: 38073374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer.
    Feng A; Tu Z; Yin B
    Oncotarget; 2016 Apr; 7(15):20507-19. PubMed ID: 26840258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in non-small cell lung cancer.
    Di Costanzo F; Mazzoni F; Micol Mela M; Antonuzzo L; Checcacci D; Saggese M; Di Costanzo F
    Drugs; 2008; 68(6):737-46. PubMed ID: 18416583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating plasminogen activator inhibitor-1 activity: a biomarker for resectable non-small cell lung cancer?
    Sotiropoulos GP; Kotopouli M; Karampela I; Christodoulatos GS; Antonakos G; Marinou I; Vogiatzakis E; Lekka A; Papavassiliou AG; Dalamaga M
    J BUON; 2019; 24(3):943-954. PubMed ID: 31424646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
    Suwinski R; Giglok M; Galwas-Kliber K; Idasiak A; Jochymek B; Deja R; Maslyk B; Mrochem-Kwarciak J; Butkiewicz D
    BMC Cancer; 2019 May; 19(1):427. PubMed ID: 31068179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.